Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
COEP 
Coeptis Therapeutics Inc (COEP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: COEP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -45.35% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 70.57M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 1 | Beta -0.5 | 52 Weeks Range 2.31 - 19.19 | Updated Date 11/6/2025 |
52 Weeks Range 2.31 - 19.19 | Updated Date 11/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.87 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2252.94% |
Management Effectiveness
Return on Assets (TTM) -98.25% | Return on Equity (TTM) -372.12% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 78458996 | Price to Sales(TTM) 267.76 |
Enterprise Value 78458996 | Price to Sales(TTM) 267.76 | ||
Enterprise Value to Revenue 297.69 | Enterprise Value to EBITDA -0.64 | Shares Outstanding 4820317 | Shares Floating 4203172 |
Shares Outstanding 4820317 | Shares Floating 4203172 | ||
Percent Insiders 13.39 | Percent Institutions 3.03 |
Upturn AI SWOT
Coeptis Therapeutics Inc
Company Overview
History and Background
Coeptis Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies. Founded with a vision to address unmet medical needs, the company has evolved through various stages of research, development, and strategic partnerships.
Core Business Areas
- Cell Therapy: Development and commercialization of cell therapy products for various diseases.
- Drug Development: Focus on discovering and developing novel therapeutics to address unmet medical needs.
Leadership and Structure
Information regarding leadership team and structure can be found in Coeptis Therapeutics Inc's (COEP) latest annual report.
Top Products and Market Share
Key Offerings
- CD38-GEAR-NK: CD38-GEAR-NK cell therapy targets CD38-expressing hematological malignancies. Clinical trials are ongoing. Competitors include companies developing similar NK cell therapies.
- Consensi: Consensiu2122 is a combination of amlodipine besylate and celecoxib for pain relief and hypertension, currently marketed outside the U.S.. Competitors include those with NSAIDs and antihypertensive medications.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by intense competition, rapid technological advancements, and high regulatory hurdles. Companies are constantly striving to innovate and develop new therapies to address unmet medical needs.
Positioning
Coeptis Therapeutics aims to establish itself as a leader in cell therapy and drug development. Its competitive advantage lies in its innovative technologies and strategic partnerships.
Total Addressable Market (TAM)
The TAM for cell therapies and related treatments is substantial, projected to be in billions of dollars. Coeptis is positioned to capture a portion of this market with its innovative products.
Upturn SWOT Analysis
Strengths
- Innovative technology platforms
- Experienced management team
- Strategic partnerships
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Dependence on key partnerships
- Early stage of development
- Reliance on external funding
Opportunities
- Expanding into new therapeutic areas
- Securing additional funding
- Forming new partnerships
- Advancing clinical trials
Threats
- Regulatory hurdles
- Competition from larger companies
- Clinical trial failures
- Economic downturn
Competitors and Market Share
Key Competitors
- ZYME
- GILD
- JNJ
Competitive Landscape
Coeptis Therapeutics faces competition from established pharmaceutical companies. Its success depends on its ability to differentiate its products and execute its strategy effectively.
Growth Trajectory and Initiatives
Historical Growth: Coeptis Therapeutics' growth is tied to clinical trial progress and commercialization of its products.
Future Projections: Future projections depend on successful completion of clinical trials and securing regulatory approvals.
Recent Initiatives: Recent initiatives include advancing clinical trials for its cell therapy candidates and pursuing strategic partnerships.
Summary
Coeptis Therapeutics is a pharmaceutical company with an innovative focus but faces resource constraints. Its cell therapy programs show promise, but successful clinical trials and partnerships are essential. The company needs to navigate regulatory hurdles and competition from larger players to achieve its growth objectives.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Financial News Sources
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share information is based on estimates and may not be precise. Financial data should be verified from official sources.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Coeptis Therapeutics Inc
Exchange NASDAQ | Headquaters Wexford, PA, United States | ||
IPO Launch date 2020-12-17 | Co-Founder, Chairman of the Board, CEO & President Mr. David Mehalick | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://coeptistx.com |
Full time employees 5 | Website https://coeptistx.com | ||
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy technology. Its product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological and solid tumors. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.